Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has shared an update.
Mochida Pharmaceutical will conduct a secondary offering of 1,153,600 existing common shares through a purchase and underwriting arrangement, with pricing to be set in early April based on market demand and recent Tokyo Stock Exchange trading levels. The shares will be sold by major shareholders Taisho Pharmaceutical Holdings and Sumitomo Pharma, and underwriters will retain the spread between the offer and purchase prices as commission.
In addition, the company is preparing a potential over-allotment offering of up to 173,000 shares, to be lent by certain shareholders and priced in line with the main secondary offering, which may or may not be executed depending on demand. The transaction is expected to increase the stock’s liquidity and modestly broaden its free float without issuing new shares, thereby reshaping Mochida’s shareholder base while avoiding dilution for existing investors.
The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3985.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japan-based drug maker listed on the Tokyo Stock Exchange Prime Market under securities code 4534. The company operates in the pharmaceutical industry, developing and selling prescription medicines and related healthcare products for the domestic market and potentially overseas partners and stakeholders.
YTD Price Performance: 4.38%
Average Trading Volume: 37,141
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen125.6B
See more data about 4534 stock on TipRanks’ Stock Analysis page.